Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00241Source: DataRank Database

GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer is a research paper published in Frontiers in Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.82)OA: goldTopics (25)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Jinlu Ma ORCID,Justin Avery ORCID,Vijaya Sambandam,Theresa Nguyen ORCID,Bo Xu ORCID

Live enrichment

PubMed:32185127 PMC:PMC7058788 OpenAlex:https://openalex.org/W3006864319

National Institutes of Health

Grant: 5RO1CA183921-05

NCI NIH HHS

Grant: R01 CA183921

National Institutes of Health

Grant: 5R01CA183921-03

Targeting GLI-dependent Transcription by GANT61 in Colon Cancer

FWCI

0.82

Citation Percentile

0.7%

Citation Trend

2020

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.3389/fonc.2020.00241

publisherhttps://doi.org/10.3389/fonc.2020.00241

publisherhttps://www.frontiersin.org/article/10.3389/fonc.2020.00241/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32185127

repositoryhttps://doaj.org/article/00de545de3a84180bfc309628ab6dd67

Fields of Study

Hedgehog Signaling Pathway StudiesCancer-related Molecular PathwaysChromatin Remodeling and Cancer03 medical and health sciences0302 clinical medicine

Keywords

Colorectal cancerCancer researchMedicineCancerTranscription factorGLI1Transcription (linguistics)OncologyPharmacologyInternal medicineBiologyGeneGeneticsDNA damage repairtarget therapy5-Fu ResistanceGli1 Target GeneNovel Gli1 InhibitorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer

FAIR Checklist

Authors (8)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)